XML 216 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1

Other Disclosures (Tables)

12 Months Ended

Dec. 31, 2021

Other Disclosures

Summary of remuneration of the Board of Directors and Executive Management

​

​	​	​	​	​	​	​
(DKK million)	​	2021	​	2020	​	2019
​	​	​	​	​	​	​
​	​	​	​	​	​	​
Wages and salaries	​	51	​	48	​	42
Share-based compensation expenses	​	58	​	43	​	38
Defined contribution plans	​	2	​	2	​	1
​	​	​	​	​	​	​
Total	​	111	​	93	​	81

Schedule of Remuneration to the Board of Directors

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

(DKK million)

Base board fee

​

Committee fees

​

Share-based compensation expenses

​

2021

​

Base board fee

​

Committee fees

​

Share-based compensation expenses

​

2020

​

Base board fee

​

Committee fees

​

Share-based compensation expenses

​

2019

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Deirdre P. Connelly

1.2

​

0.5

​

0.7

​

2.4

​

1.1

​

0.5

​

0.7

​

2.3

​

0.8

​

0.5

​

0.9

​

2.2

Pernille Erenbjerg

0.9

​

0.4

​

0.5

​

1.8

​

0.7

​

0.4

​

0.4

​

1.5

​

0.4

​

0.3

​

0.4

​

1.1

Mats Pettersson1

-

​

-

​

-

​

-

​

0.3

​

0.1

​

1.6

​

2.0

​

1.2

​

0.2

​

0.8

​

2.2

Anders Gersel Pedersen

0.6

​

0.4

​

0.4

​

1.4

​

0.4

​

0.4

​

0.5

​

1.3

​

0.4

​

0.4

​

0.6

​

1.4

Paolo Paoletti

0.6

​

0.3

​

0.4

​

1.3

​

0.4

​

0.3

​

0.4

​

1.1

​

0.4

​

0.3

​

0.4

​

1.1

Rolf Hoffmann

0.6

​

0.4

​

0.4

​

1.4

​

0.4

​

0.3

​

0.5

​

1.2

​

0.4

​

0.3

​

0.8

​

1.5

Jonathan Peacock2

0.5

​

0.3

​

0.6

​

1.4

​

0.3

​

0.3

​

0.4

​

1.0

​

-

​

-

​

-

​

-

Peter Storm Kristensen5

0.6

​

-

​

0.4

​

1.0

​

0.4

​

-

​

0.4

​

0.8

​

0.4

​

-

​

0.4

​

0.8

Rick Hibbert4,5

-

​

-

​

-

​

-

​

-

​

-

​

-

​

-

​

0.1

​

-

​

0.4

​

0.5

Rima Bawarshi Nassar3,5

0.6

​

-

​

0.2

​

0.8

​

0.1

​

-

​

-

​

0.1

​

-

​

-

​

-

​

-

Mijke Zachariasse5

0.6

​

-

​

0.3

​

0.9

​

0.4

​

-

​

0.1

​

0.5

​

0.3

​

-

​

-

​

0.3

Daniel J. Bruno3,5

-

​

-

​

-

​

-

​

0.3

​

-

​

(0.4)

​

(0.1)

​

0.4

​

-

​

0.4

​

0.8

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Total

6.2

​

2.3

​

3.9

​

12.4

​

4.8

​

2.3

​

4.6

​

11.7

​

4.8

​

2.0

​

5.1

​

11.9

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

1 – Mats Pettersson stepped down from the Board of Directors at the Annual General Meeting in March 2020.

2 – Jonathan Peacock stepped down from the Board of Directors effective November 15, 2021, due to increased responsibilities in connection with his other board commitments.

3 – Daniel J. Bruno stepped down from the Board of Directors and Rima Bawarshi Nassar replaced Daniel J. Bruno on the Board of Directors as an employee elected board member during August 2020.

4 – Rick Hibbert stepped down from the Board of Directors at the Annual General Meeting in March 2019.

5 – Employee elected board member

Schedule of executive compensation

​

​	​	​	​	​	​	​	​	​	​	​	​
​	2021
​	Base Salary	​	Defined Contribution Plans	​	Other Benefits	​	Annual Cash Bonus	​	Share-Based Compensation Expenses	​	Total
(DKK million)	​	​	​	​	​	​	​	​	​	​	​
​	​	​	​	​	​	​	​	​	​	​	​
Jan van de Winkel	7.9	​	1.1	​	0.6	​	7.9	​	20.6	​	38.1
Anthony Pagano	3.2	​	0.1	​	-	​	1.9	​	7.2	​	12.4
Anthony Mancini	3.9	​	0.1	​	3.1	​	2.3	​	7.2	​	16.6
Judith Klimovsky	4.0	​	0.1	​	-	​	2.5	​	13.2	​	19.8
Tahamtan Ahmadi1	3.3	​	0.1	​	-	​	2.0	​	5.5	​	10.9
​	​	​	​	​	​	​	​	​	​	​	​
Total	22.3	​	1.5	​	3.7	​	16.6	​	53.7	​	97.8
​	​	​	​	​	​	​	​	​	​	​	​

​

1 – Tahamtan Ahmadi was appointed Chief Medical Officer, Head of Experimental Medicines and member of the Executive Management in March 2021.

​

​	​	​	​	​	​	​	​	​	​	​	​
​	2020
​	Base Salary	​	Defined Contribution Plans	​	Other Benefits	​	Annual Cash Bonus	​	Share-Based Compensation Expenses	​	Total
(DKK million)	​	​	​	​	​	​	​	​	​	​	​
​	​	​	​	​	​	​	​	​	​	​	​
Jan van de Winkel	7.3	​	1.0	​	1.0	​	8.4	​	19.6	​	37.3
Anthony Pagano1	3.0	​	0.1	​	-	​	2.3	​	5.2	​	10.6
Anthony Mancini2	3.1	​	0.1	​	3.3	​	2.0	​	3.1	​	11.6
Judith Klimovsky	4.0	​	0.1	​	0.1	​	3.0	​	12.7	​	19.9
David A. Eatwell1	0.9	​	0.1	​	2.5	​	-	​	(2.3)	​	1.2
​	​	​	​	​	​	​	​	​	​	​	​
Total	18.3	​	1.4	​	6.9	​	15.7	​	38.3	​	80.6

​

1 – David A. Eatwell stepped down as CFO on February 29, 2020, and Anthony Pagano was appointed CFO and member of the Executive Management on March 1, 2020.

2 – Anthony Mancini was appointed Chief Operating Officer and member of the Executive Management in March 2020.

​

​ ​	​	​	​	​	​	​	​	​	​	​	​
​	2019
​	Base Salary	​	Defined Contribution Plans	​	Other Benefits	​	Annual Cash Bonus	​	Share-Based Compensation Expenses	​	Total
(DKK million)	​	​	​	​	​	​	​	​	​	​	​
​	​	​	​	​	​	​	​	​	​	​	​
Jan van de Winkel	7.3	​	1.0	​	3.6	​	8.4	​	14.9	​	35.2
David A. Eatwell	4.3	​	0.1	​	0.9	​	3.2	​	8.0	​	16.5
Judith Klimovsky	4.1	​	0.1	​	-	​	3.1	​	9.7	​	17.0
​	​	​	​	​	​	​	​	​	​	​	​
Total	15.7	​	1.2	​	4.5	​	14.7	​	32.6	​	68.7

Schedule of company overview

​

​	​	​ ​	​ ​
Name	Domicile	Ownership and votes 2021	Ownership and votes 2020
Genmab B.V.	Utrecht, the Netherlands	100%	100%
Genmab Holding B.V.	Utrecht, the Netherlands	100%	100%
Genmab US, Inc.	New Jersey, USA	100%	100%
Genmab K.K.	Tokyo, Japan	100%	100%

Summary of fees to auditors

​

​	​	​	​	​	​	​
(DKK million)	​	2021	​	2020	​	2019
​	​	​	​	​	​	​
​	​	​	​	​	​	​
PricewaterhouseCoopers	​	​	​	​	​	​
Audit fees	​	5.8	​	4.9	​	1.9
Audit-related fees	​	1.8	​	1.0	​	2.3
Tax fees	​	-	​	0.3	​	0.5
All other fees	​	0.1	​	-	​	2.4
​	​	​	​	​	​	​
Total	​	7.7	​	6.2	​	7.1

Summary of adjustments to cash flow statement

​

​	​	​	​	​	​	​	​
(DKK million)	Note	​	2021	​	2020	​	2019
​	​	​	​	​	​	​	​
​	​	​	​	​	​	​	​
Adjustments for non-cash transactions:	​	​	​	​	​	​	​
Depreciation, amortization and impairment	3.1, 3.2, 3.3	​	248	​	259	​	139
Share-based compensation expenses	2.3, 4.6	​	310	​	200	​	147
Other	​	​	(32)	​	-	​	5
​	​	​	​	​	​	​	​
Total adjustments for non-cash transactions	​	​	526	​	459	​	291
​	​	​	​	​	​	​	​
Change in operating assets and liabilities:	​	​	​	​	​	​	​
Receivables	​	​	(1,074)	​	306	​	(1,658)
Deferred revenue	​	​	-	​	513	​	-
Other payables	​	​	304	​	168	​	440
​	​	​	​	​	​	​	​
Total change in operating assets and liabilities	​	​	(770)	​	987	​	(1,218)

X

- Definition

The tabular disclosure of amounts incurred by entity for provision of key management personnel .

+ References

No definition available.

+ Details

Name:	gmab_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelTableTextBlock
Namespace Prefix:	gmab_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

No definition.

+ References

No definition available.

+ Details

Name:	gmab_OtherDisclosureAbstract
Namespace Prefix:	gmab_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of amounts incurred by the entity for provision of key management personnel services that are provided by separate management entities. [Refer: Key management personnel of entity or parent [member]; Separate management entities [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 24
-IssueDate 2021-01-01
-Paragraph 18A
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18A&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of compensation to the entity's auditors.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 10
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_DisclosureOfAuditorsRemunerationExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for a statement of cash flows.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Section Presentation of a statement of cash flows
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS07_g10-17_TI
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_DisclosureOfCashFlowStatementExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 10
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph 2
-Subparagraph b
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_2_b_i&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration